论文部分内容阅读
树突状细胞(DCS)是最重要的抗原递呈细胞(APCS),它具有独特的刺激T淋巴细胞使其成为肿瘤特异性细胞毒T淋巴细胞的能力,体外肿瘤抗原冲击的DCS用作“疫苗”回输肿瘤已在国内外受到广泛关注。研究证实,DCS可由造血干细胞及外周血单核细胞等多种细胞诱导而来,我们将分离妇科肿瘤患者外周血得到的单核细胞在白介素4、粒单细胞集落刺激因子(GM-CSF)作用下于体外诱导DCS的生成和向成熟分化,以此制成疫苗给患者行皮下注射,观察治疗后患者肿瘤的情况及其T淋巴细胞亚群的变化,同时在体外观察DCS激活淋巴细胞产生CTL及CTL对肿瘤细胞的杀伤效应。
Dendritic cells (DCS) are the most important antigen-presenting cells (APCs) with unique ability to stimulate T lymphocytes to become tumor-specific cytotoxic T lymphocytes and in vitro tumor antigen challenged DCS as a “Vaccine” tumor return has received widespread attention at home and abroad. Studies have shown that DCS can be induced by a variety of cells such as hematopoietic stem cells and peripheral blood mononuclear cells. We isolated monocytes from peripheral blood of patients with gynecologic cancer by interfering with interleukin-4 and GM-CSF In vitro induction of DCS generation and differentiation to mature, as a vaccine made to patients subcutaneously to observe the patient’s tumor after treatment and changes in T lymphocyte subsets, while in vitro observation of DCS activated lymphocytes produce CTL And CTL killing effect on tumor cells.